// App-Quantinova.ai

1301-203 : PAR-1 ANTAGONIST VORAPAXAR IMPROVES GLOBAL THROMBOTIC STATUS IN PATIENTS WITH CORONARY DISEASE

Researchers

Presenter

  • Diana A. Gorog

Principal Investigators

  • Christos Christopoulos

  • Maria N. Niespialowska-Steuden

  • Robert Kozarski

  • Robert Wilcox

Medical Centers

  • Imperial College, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Acute Coronary Syndromes

  • Coronary Artery Disease

  • Venous thrombosis

Biomarkers

  • T cell receptor alpha locus

Drug/Treatment

  • Vorapaxar

  • Evithrom

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved